BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Clinical trial supply company strengthens its presence in the European Union
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Modi holds a bachelor's degree in Chemical Engineering from University of Cincinnati and a master’s degree in Marketing, Management Strategy and Finance from Northwestern’s Kellogg School of Management
This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Subscribe To Our Newsletter & Stay Updated
